http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#Head
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#provenance
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#pubinfo
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion
http://purl.obolibrary.org/obo/DOID_10933
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10933
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00472
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
http://www.w3.org/2000/01/rdf-schema#label
fluoxetine capsules usp are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd in adult and pediatric patients aged 8 to 18 years 1 1 acute and maintenance treatment of obsessive compulsive disorder ocd in adult and pediatric patients aged 7 to 17 years 1 2 acute and maintenance treatment of bulimia nervosa in adult patients 1 3 acute treatment of panic disorder with or without agoraphobia in adult patients 1 4 fluoxetine capsules usp and olanzapine in combination acute treatment of depressive episodes associated with bipolar i disorder in adults 1 5 fluoxetine capsules usp are indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to 18 years see clinical studies 14 1 the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re evaluated see dosage and administration 2 1 fluoxetine capsules usp are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder ocd see clinical studies 14 2 the effectiveness of fluoxetine capsules usp in long term use i e for more than 13 weeks has not been systematically evaluated in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 2 fluoxetine capsules usp are indicated for the acute and maintenance treatment of binge eating and vomiting behaviors in adult patients with moderate to severe bulimia nervosa see clinical studies 14 3 the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 3 fluoxetine capsules usp are indicated for the acute treatment of panic disorder with or without agoraphobia in adult patients see clinical studies 14 4 the effectiveness of fluoxetine capsules usp in long term use i e for more than 12 weeks has not been established in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 4 when using fluoxetine capsules usp and olanzapine in combination also refer to the clinical studies section of the package insert for olanzapine and fluoxetine hydrochloride capsules fluoxetine capsules usp and olanzapine in combination is indicated for the acute treatment of depressive episodes associated with bipolar i disorder in adult patients fluoxetine capsules usp monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00472
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#provenance
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#pubinfo
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig
http://purl.org/nanopub/x/hasSignature
aqwx3O5MBt/6UgUtYoLgi7x3tnv2ygQvPXRiDTUG8UPhg/n/1RfkLR7a4k+TKUNaSlaoNeD7NqevVEAeFEWiUbWKygkc8tXNwEA/nAgA0tJWTBbe66Bd6Un4zb+nqXaKvyk2YG7m0yJlW30Ok0b2Jx58fsVQMk9QIPNMpxU2IB8=
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://purl.org/dc/terms/created
2021-06-15T18:01:37.131+02:00
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs